These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9354921)

  • 1. Quality control of biomarker measurement in epidemiology.
    Gompertz D
    IARC Sci Publ; 1997; (142):215-22. PubMed ID: 9354921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.
    Schmitt M; Harbeck N; Daidone MG; Brynner N; Duffy MJ; Foekens JA; Sweep FC
    Int J Oncol; 2004 Nov; 25(5):1397-406. PubMed ID: 15492831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
    Sweep FC; Fritsche HA; Gion M; Klee GG; Schmitt M;
    Int J Oncol; 2003 Dec; 23(6):1715-26. PubMed ID: 14612946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality requirements and control: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2791-4. PubMed ID: 10470242
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry.
    Hsu FD; Nielsen TO; Alkushi A; Dupuis B; Huntsman D; Liu CL; van de Rijn M; Gilks CB
    Mod Pathol; 2002 Dec; 15(12):1374-80. PubMed ID: 12481020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic DHPLC Quality Assurance (DDQA): a collaborative approach to the generation of validated and standardized methods for DHPLC-based mutation screening in clinical genetics laboratories.
    Schollen E; Dequeker E; McQuaid S; Vankeirsbilck B; Michils G; Harvey J; van den Akker E; van Schooten R; Clark Z; Schrooten S; Matthijs G;
    Hum Mutat; 2005 Jun; 25(6):583-92. PubMed ID: 15880509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External quality control program for inter-laboratory quality control.
    Bewarder N; Müller P
    Anticancer Res; 2000; 20(6D):5213-6. PubMed ID: 11326697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neural network-based biomarker association information extraction approach for cancer classification.
    Wang HQ; Wong HS; Zhu H; Yip TT
    J Biomed Inform; 2009 Aug; 42(4):654-66. PubMed ID: 19162234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample collection, processing and storage.
    Landi MT; Caporaso N
    IARC Sci Publ; 1997; (142):223-36. PubMed ID: 9354922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of biomarker measurement error on epidemiological studies.
    White E
    IARC Sci Publ; 1997; (142):73-93. PubMed ID: 9354913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer.
    Mengel M; Hebel K; Kreipe H; von Wasielewski R
    Breast J; 2005; 11(1):34-40. PubMed ID: 15647076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality control in tumor marker values: methology, results and potential problems].
    Ben Ayed M; Ben Hadj Hmida Y; Kassis M; Damak J; Masmoudi H
    Tunis Med; 2001; 79(6-7):341-7. PubMed ID: 11771428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour markers in breast cancer--EGTM recommendations. European Group on Tumor Markers.
    Anticancer Res; 1999; 19(4A):2803-5. PubMed ID: 10470245
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumour markers in germ cell cancer: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2795-8. PubMed ID: 10470243
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene expression analysis and clinical diagnosis.
    Sandvik AK; Alsberg BK; Nørsett KG; Yadetie F; Waldum HL; Laegreid A
    Clin Chim Acta; 2006 Jan; 363(1-2):157-64. PubMed ID: 16168978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality assurance issues and interpretation of assays.
    Mackie I; Cooper P; Kitchen S
    Semin Hematol; 2007 Apr; 44(2):114-25. PubMed ID: 17433904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery.
    Habis AH; Vernon SD; Lee DR; Verma M; Unger ER
    Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):492-6. PubMed ID: 15006929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational crossroads for biomarkers.
    Bast RC; Lilja H; Urban N; Rimm DL; Fritsche H; Gray J; Veltri R; Klee G; Allen A; Kim N; Gutman S; Rubin MA; Hruszkewycz A
    Clin Cancer Res; 2005 Sep; 11(17):6103-8. PubMed ID: 16144908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244
    [No Abstract]   [Full Text] [Related]  

  • 20. Transitional studies.
    Schulte PA; Perera FP
    IARC Sci Publ; 1997; (142):19-29. PubMed ID: 9354908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.